We are live on ! Find out more
ABI

Adamant Biomedical Investments Portfolio holdings

AUM $418M
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
Cap. Flow
-$20M
Cap. Flow %
-4.77%
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7

Top Buys

Rank Stock Value
1
HSP
HOSPIRA INC
HSP
+$5.08M
2
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$4.94M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$4.68M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$4.24M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$4.8M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.11M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.02M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.9M
5
QGENF
QIAGEN NV
QGENF
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 87.28%
2 Financials 0.93%
3 Industrials 0.35%
4 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
101
Insulet
PODD
$9.79B
– –
-80,000
Closed -$2.95M
TNA icon
102
Direxion Daily Small Cap Bull 3x ETF
TNA
$1.47B
– –
-60,000
Closed -$1.9M
VIVS
103
VivoSim Labs
VIVS
$1.64M
– –
-208
Closed -$319K
RVNC
104
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-130,000
Closed -$2.51M
WMGI
105
DELISTED
Wright Medical Group Inc
WMGI
– –
-38,000
Closed -$1.15M
LDRH
106
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
– –
-33,000
Closed -$1.03M
DNDN
107
DELISTED
DENDREON CORPORATION
DNDN
– –
-50,000
Closed -$72K
1 2 3 4
5

Similar funds

AGCJ
Alden Global Capital (Jersey) St. Helier, Jersey $415M AUM 31.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
RNS
Robert N. Shapiro $501M AUM 11.7% 1-Year Est. Return
NTP
Nine Ten Partners Evanston, Illinois $308M AUM
MMC
MDV Management Company Menlo Park, California $296M AUM
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
CAMI
Concord Asset Management (Illinois) Chicago, Illinois $288M AUM 11.06% 1-Year Est. Return
NES
New England Securities New York $285M AUM 7.18% 1-Year Est. Return

Adamant Biomedical Investments's Q4 2014 Portfolio in Review

As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Financials and Industrials.

Against the trend, Adamant Biomedical Investments opened a new position in HOSPIRA INC worth $5.51M.

  • Adamant Biomedical Investments's largest Q4 2014 buy was HOSPIRA INC: 90,000 shares worth $5.51M.
  • Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
  • Adamant Biomedical Investments's biggest Q4 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $4.8M.
  • Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
  • Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
  • Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
  • Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.